New eye drop shows promise for glaucoma patients

NCT ID NCT06144918

Completed Disease control Sponsor: Skye Bioscience, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new eye drop called SBI-100 in 56 adults with glaucoma or high eye pressure. Participants received either a low dose, high dose, or placebo drop twice daily for 14 days. Researchers measured how well the drops lowered eye pressure and checked for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SBI-100 ophthalmic emulsion (eye drop)
What this could lead to: If successful, this could lead to a new eye drop treatment to lower pressure in the eye for people with glaucoma or ocular hypertension.
What could go wrong: This is an early Phase 2 trial with only 56 participants, so results may not apply to everyone. The treatment may not work better than placebo or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OCULAR HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OCULAR HYPERTENSION PRIMARY OPEN ANGLE GLAUCOMA

Contacts and locations

Locations

Eye Research Foundation

Newport Beach, California, 92663, United States
Global Research Management, Inc.

Glendale, California, 91204, United States
Scott & Christie and Associates, PC

Cranberry Township, Pennsylvania, 16066, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.